Dr. Paige E. Sutton, M.D.
Neurology (Neurology Physician)
- Medicare participating
At a glance
- Medical school
- Wright State University Boonshoft School of Medicine (2017)
- Years since graduation
- 9
- In the NPI registry since
- 2017
- Medicare patients seen, 2024
- 81
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2017Medical school: Wright State University Boonshoft School of Medicine
- 2017Registered with an NPI (national billing number; not a license date)
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Neurology Physician primary
OH license 35.144482 · KY license R4593
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Riverside Methodist Hospital Columbus, OH
- Grant Medical Center Columbus, OH
- Berger Hospital Circleville, OH
Medical groups
- Ohiohealth Corporation (2,314 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 81
- Services billed
- 19,412
- Patients’ average age
- 70
| Service | Times | Patients |
|---|---|---|
| Injection of chemical for paralysis of nerve muscles on arm or leg, 5 or more muscles, first extremity | 23 | 12 |
| Established patient office or other outpatient visit, 40-54 minutes | 23 | 17 |
| Needle measurement of electrical activity in muscle with injection of chemical for paralysis of nerve muscle | 22 | 11 |
| Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | 21 | 21 |
| New patient office or other outpatient visit, 60-74 minutes | 18 | 18 |
| Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | 16 | 12 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Baclofen Other prescribers in Columbus, OH | 42 |
| Gabapentin Other prescribers in Columbus, OH | 27 |
| Teriflunomide | 27 |
| Levetiracetam Other prescribers in Columbus, OH | 14 |
| Pregabalin Other prescribers in Columbus, OH | 14 |
| Dalfampridine Er (dalfampridine) | 13 |
| Lacosamide Other prescribers in Columbus, OH | 13 |
| Azathioprine Other prescribers in Columbus, OH | 11 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 6 companies reported 10 payments worth $747 in total to this clinician.
| Alexion Pharmaceuticals, Inc. | $304 |
|---|---|
| Biogen, Inc. | $150 |
| Novartis Pharmaceuticals Corporation | $109 |
| EMD Serono, Inc. | $94.52 |
| Tg Therapeutics, Inc. | $73.38 |
| Amgen Inc. | $16.87 |
| Food and Beverage | $367 |
|---|---|
| Consulting Fee | $325 |
| Education | $55.50 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Alexion Pharmaceuticals, Inc. Mar 27, 2025 | Consulting Fee ULTOMIRIS · Rare Disease | $175 |
| Biogen, Inc. May 14, 2025 | Consulting Fee TYSABRI · Neurology | $150 |
| EMD Serono, Inc. May 21, 2025 | Education in-kind Company’s descriptionReprints | $55.50 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 1 industry-funded study in 2025, from 1 company. The companies reported $18,005 in research payments for these studies, mostly to the institutions running them.
- Efficacy and Safety Studies of Frexalimab (SAR441344) in Adults With Relapsing Forms of Multiple Sclerosis
Genzyme Corporation · Active, not recruiting · NCT06141473
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.